BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, March 2, 2026
Home » Topics » Science » Drug design, drug delivery and technologies

Drug design, drug delivery and technologies
Drug design, drug delivery and technologies RSS Feed RSS

Microscope with beakers and flasks
Drug design, drug delivery & technologies

Tevogen Bio expands Microsoft AI-powered collaboration

Jan. 27, 2025
Tevogen Bio Holdings Inc. has expanded its relationship with Microsoft Corp. to broaden their AI-focused collaboration and build its Predictcell technology for predictive precision T-cell targeting.
Read More
Illustration of cobra in front of protein structures

An antidote to cobra venom designed with AI

Jan. 22, 2025
By Mar de Miguel
Following Nobel Prize-winning chemist David Baker’s recipe for cooking an antidote to cobra venom using artificial intelligence (AI) could be faster and more effective than currently available methods. The ingredients and steps can be found in a new study published by the University of Washington scientist in collaboration with the Technical University of Denmark. They are ready for the next steps in preclinical trials.
Read More
DNA in test tubes
Drug design, drug delivery & technologies

Circio partners with 4basbio on synthetic Circvec DNA vectors

Jan. 21, 2025
Circio Holding ASA has entered a partnership with 4basebio plc for joint development and in vivo delivery testing of synthetic Circvec DNA vectors.
Read More
Illustration of cobra in front of protein structures
Substance use & poisoning

An antidote to cobra venom designed with AI

Jan. 21, 2025
By Mar de Miguel
Following Nobel Prize-winning chemist David Baker’s recipe for cooking an antidote to cobra venom using artificial intelligence (AI) could be faster and more effective than currently available methods. The ingredients and steps can be found in a new study published by the University of Washington (UW) scientist in collaboration with the Technical University of Denmark. They are ready for the next steps in preclinical trials.
Read More
Scanning electron micrograph of M. tuberculosis
Respiratory

In monkeys, enhanced TB vaccine dissolves after inducing protection

Jan. 14, 2025
By Mar de Miguel
An experimental tuberculosis (TB) vaccine with a dual mission – self-destruction after inducing immunity – improved the design of the Bacillus Calmette-Guérin (BCG) immunotherapy, a vaccine also used against cancer. Scientists at the University of Pittsburgh engineered this strain with a double break, which is effective and safer after an intravenous administration, according to their results in nonhuman primates and mice.
Read More
Blood samples in lab
Drug design, drug delivery & technologies

Proteomics study explores how protein changes influence disease

Jan. 13, 2025
By Nuala Moran
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to assess the levels of 5,400 different proteins.
Read More
Drug capsule spilling onto brain
Neurology/psychiatric

Tenvie Therapeutics launches with focus on neurological diseases

Jan. 9, 2025
The company is advancing a pipeline of therapeutics, including programs acquired from Denali Therapeutics Inc., focused on treating neurological, cardiometabolic and ophthalmic diseases.
Read More
Drug R&D concept image.
Cancer

Rakovina advances synthesis of PARP1-selective inhibitors

Jan. 7, 2025
Rakovina Therapeutics Inc. has announced the successful synthesis of novel small-molecule drug candidates designed under the company’s artificial intelligence (AI) platform collaboration.
Read More
Female researcher wearing mask and safety glasses holding dropper
Drug design, drug delivery & technologies

Institut Pasteur Korea and POSTECH institutes to collaborate on infectious disease research

Jan. 3, 2025
Institut Pasteur Korea has signed a memorandum of understanding (MOU) with four Pohang University of Science and Technology (POSTECH)-affiliated research institutes with the aim of pursuing joint research on mRNA vaccine and treatment development.
Read More
Nanoparticle illustration
Drug design, drug delivery & technologies

Altamira Therapeutics achieves nanoparticle-based delivery of circular mRNA

Jan. 2, 2025
Altamira Therapeutics Ltd.’s nanoparticle-based delivery platform has been successfully tested for circular mRNA.
Read More
Previous 1 2 … 14 15 16 17 18 19 20 21 22 … 410 411 Next

Popular Stories

  • Today's news in brief

    BioWorld
  • Brain and virus with chromosome

    CROI 2026: Neurodegeneration, the challenge of aging with HIV

    BioWorld
    Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
  • Depression concept with human, broken brain and heavy rain

    CROI 2026 highlights depression and cognitive vulnerability in HIV

    BioWorld
    The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for Feb. 24, 2026
  • University of Southern California reports new MAPT aggregation inhibitors

    BioWorld Science
    The University of Southern California has identified (2-oxo-2H-chromen-3-yl) scaffold-based carboxamide analogues acting as potent microtubule-associated protein...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing